John Ducker

President, Region U.S.
Fresenius Kabi

John Ducker is President, Region U.S., for Fresenius Kabi and a member of the company’s global Management Board. Fresenius Kabi is a global health care company that specializes in lifesaving medicines and medical technologies for infusion, transfusion and clinical nutrition. The company’s products are used to help care for patients with critical and chronic conditions. Fresenius Kabi is a past recipient of the FDA’s Drug Shortage Assistance Award.

Fresenius Kabi has deep expertise in four areas: pharmaceuticals such as injectable medicines in vials, syringes and flexible IV bags; biopharmaceuticals including biosimilar medicines used to treat cancer and immune disorders; clinical nutrition such as intravenous lipids; and medical technologies such as infusion systems and IV pumps, and technologies used to collect, separate and store blood and blood components, and produce cell therapies. Fresenius Kabi fills and finishes more than 70% of its pharmaceutical products in America, including more than 500 million doses of essential medicines a year.

In his current role as president, Region U.S., Mr. Ducker is responsible for the company’s strategy and commercial operations in the United States.  He is also a member of the board of directors of AAM, the Association for Accessible Medicines, the leading U.S. trade association for generic and biosimilar medicines.

Mr. Ducker joined Fresenius Kabi in 1989 as a manufacturing manager in the United Kingdom.  His career has advanced through numerous leadership positions of increasing responsibility. He has led Fresenius Kabi’s businesses in the UK, Ireland, the Benelux countries, Scandinavia, South Africa, Canada, and Greece. He has also led Strategic Portfolio management, Global R&D, Medical and Clinical Affairs and Regulatory Affairs for the company worldwide. 

Mr. Ducker holds a bachelor’s and a master’s degree in Chemical Engineering from University of Cambridge in England.